10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
A novel gene therapy program developed at University College London (UCL), the first project to be supported by Apollo Therapeutics, has been licensed to healthcare investment firm Deerfield. 21 July 2020
US clinical-stage biotech Pieris Pharmaceuticals has announced that its Phase I studies of PRS-343 have been placed on partial clinical hold by the US Food and Drug Administration 21 July 2020
There was nothing to deter investors, governments and populations in a set of interim results from the ongoing Phase I/II COV001 trial of AZD1222, a COVID-19 vaccine candidate being developed by AstraZeneca and the University of Oxford. 20 July 2020
Having already signed up to receive 100 million of AstraZeneca and the University of Oxford’s investigational COVID-19 vaccine, the UK government has now gambled on two further candidates. 20 July 2020
PTC Therapeutics today announced an agreement to monetize a portion of the risdiplam royalty stream for $650 million from Royalty Pharma, with the news bringing the firm’s shares down 2.5% to $54.29 in early trading. 20 July 2020
The report by the Courier Mail and other Australia media agencies on Saturday that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect, says the country’s leading pharma company CSL Limited. 20 July 2020
Clinical-stage German biotech CureVac has signed a strategic collaboration with UK pharma major GlaxoSmithKline on mRNA vaccine and monoclonal antibody (MAb) research. 20 July 2020
US pharma major Bristol-Myers Squibb today announced that the European Medicines Agency has validated its Marketing Authorization Application (MAA) for lisocabtagene maraleucel (liso-cel). 17 July 2020
Eli Lilly today announced that its mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of interleukin (IL)23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study. 17 July 2020
Nerlynx, (neratinib), a new breast cancer drug shown to significantly reduce the risk of cancer recurrence, is now approved for use in Malaysia. 17 July 2020
US biotech Tricida opened more than a third lower on Thursday after announcing a setback relating to veverimer, the company’s orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). 16 July 2020
UK novel RNA therapeutics firm Silence Therapeutics says Mallinckrodt has exercised the option, under the collaboration forged in July 2019, to obtain exclusive worldwide licenses for two additional complement-targeted RNAi assets from Silence. 16 July 2020
The Japan-based Sosei Group today announced the successful completion of an international offering of new shares and euro-yen denominated convertible bonds due 2025 that has raised a total of approximately $200 million. 16 July 2020
Guangzhou, China-based LintonPharm is launching a Phase III trial program for catumaxomab in peritoneal carcinomatosis, a form of advanced gastric cancer. 16 July 2020
The European Commission has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF). 16 July 2020